EP3985022A4 - ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE - Google Patents

ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE Download PDF

Info

Publication number: EP3985022A4
Authority: EP; European Patent Office
Prior art keywords: igf1r; syn; bispecific antibody; antibody against; bispecific
Prior art date: 2019-06-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP20822425.3A

Other languages

German (de)

English (en)

Other versions

EP3985022A1 (fr

Inventor

Sungwon AN

Jinhyung Ahn

Byungje Sung

Dongin Kim

Daehae SONG

Jaehyun EOM

Yong-Gyu Son

Kyungjin PARK

Juhee Kim

Jinwon JUNG

Bora Lee

Hyesu YUN

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ABL Bio Inc

Original Assignee

ABL Bio Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-06-14

Filing date

2020-06-15

Publication date

2023-08-02

2020-06-15 Application filed by ABL Bio Inc filed Critical ABL Bio Inc

2020-06-15 Priority to EP23178097.4A priority Critical patent/EP4268842A3/fr

2022-04-20 Publication of EP3985022A1 publication Critical patent/EP3985022A1/fr

2023-08-02 Publication of EP3985022A4 publication Critical patent/EP3985022A4/fr

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP20822425.3A 2019-06-14 2020-06-15 ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE Pending EP3985022A4 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP23178097.4A EP4268842A3 (fr)	2019-06-14	2020-06-15	ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20190071057		2019-06-14
PCT/KR2020/007704 WO2020251316A1 (fr)	2019-06-14	2020-06-15	ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE α-SYN/IGF1R ET UTILISATION ASSOCIÉE

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP23178097.4A Division-Into EP4268842A3 (fr)	2019-06-14	2020-06-15	ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE
EP23178097.4A Division EP4268842A3 (fr)	2019-06-14	2020-06-15	ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE

Publications (2)

Publication Number	Publication Date
EP3985022A1 EP3985022A1 (fr)	2022-04-20
EP3985022A4 true EP3985022A4 (fr)	2023-08-02

Family

ID=73781866

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP23178097.4A Pending EP4268842A3 (fr)	2019-06-14	2020-06-15	ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE
EP20822425.3A Pending EP3985022A4 (fr)	2019-06-14	2020-06-15	ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP23178097.4A Pending EP4268842A3 (fr)	2019-06-14	2020-06-15	ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE

Country Status (17)

Country	Link
US (3)	US20220348665A1 (fr)
EP (2)	EP4268842A3 (fr)
JP (4)	JP7348676B2 (fr)
KR (2)	KR102691493B1 (fr)
CN (2)	CN117024589A (fr)
AU (2)	AU2020291487B2 (fr)
BR (1)	BR112021025086A2 (fr)
CA (1)	CA3143242A1 (fr)
CL (1)	CL2021003335A1 (fr)
CO (1)	CO2021017688A2 (fr)
EA (1)	EA202193058A1 (fr)
IL (2)	IL302490A (fr)
MX (2)	MX2021015081A (fr)
PE (2)	PE20220516A1 (fr)
PH (1)	PH12021553122A1 (fr)
WO (1)	WO2020251316A1 (fr)
ZA (1)	ZA202304485B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112019013953A2 (pt)	2017-01-06	2020-02-11	Abl Bio Inc.	Anticorpo anti-a-syn e uso do mesmo
CA3051839A1 (fr)	2017-02-17	2018-08-23	Bristol-Myers Squibb Company	Anticorps anti-alpha-synucleine et leurs utilisations
EP3725806A4 (fr)	2017-12-14	2022-03-30	ABL Bio Inc.	Anticorps bispécifique contre a-syn/igf1r et utilisation associée
TW202309076A (zh) *	2021-05-12	2023-03-01	南韓商Ａｂｌ生物公司	用於治療α-突觸核蛋白病之抗體

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015131258A1 (fr) *	2014-03-06	2015-09-11	National Research Council Of Canada	Anticorps spécifiques du récepteur du facteur de croissance 1 analogues à l'insuline et leurs utilisations
WO2019023809A1 (fr) *	2017-08-02	2019-02-07	Stressmarq Biosciences Inc.	Anticorps se liant à l'alpha-synucléine active
WO2019098763A2 (fr) *	2017-11-17	2019-05-23	에이비엘바이오 주식회사	ANTICORPS ANTI-α-SYNUCLÉINE ET LEURS UTILISATIONS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
CA2726087A1 (fr) *	2008-06-03	2009-12-10	Tariq Ghayur	Immunoglobulines a deux domaines variables et leurs utilisations
RS63930B1 (sr) *	2011-10-28	2023-02-28	Prothena Biosciences Ltd	Humanizovana antitela koja prepoznaju alfa-sinuklein
US9534044B2 (en) *	2013-02-28	2017-01-03	United Arab Emirates University	Alpha-synuclein antibodies and uses thereof
US20150093399A1 (en) *	2013-08-28	2015-04-02	Bioasis Technologies, Inc.	Cns-targeted conjugates having modified fc regions and methods of use thereof
JP2017501848A (ja) *	2013-11-19	2017-01-19	プロセナバイオサイエンシーズリミテッド	便秘症状からのレビー小体病の免疫療法のモニター
DK3114141T3 (da) *	2014-03-06	2020-08-10	Nat Res Council Canada	Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf
PE20170088A1 (es) *	2014-03-06	2017-03-09	Nat Res Council Canada	Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
JP2017536102A (ja) *	2014-10-16	2017-12-07	ジェネンテック，インコーポレイテッド	抗アルファ−シヌクレイン抗体及び使用方法
TW201734049A (zh) *	2016-01-22	2017-10-01	健生生物科技公司	抗－ｒｏｒ１抗體、ｒｏｒ１ｘｃｄ３雙特異性抗體及使用其之方法
BR112019013953A2 (pt)	2017-01-06	2020-02-11	Abl Bio Inc.	Anticorpo anti-a-syn e uso do mesmo
US10577421B2 (en) *	2017-02-22	2020-03-03	I-Mab	Anti-LAG-3 antibodies and uses thereof
EP3625258A1 (fr) *	2017-05-16	2020-03-25	Alector LLC	Anticorps anti-siglec-5 et leurs procédés d'utilisation
EP3725806A4 (fr) *	2017-12-14	2022-03-30	ABL Bio Inc.	Anticorps bispécifique contre a-syn/igf1r et utilisation associée

2020
- 2020-06-15 EP EP23178097.4A patent/EP4268842A3/fr active Pending
- 2020-06-15 CN CN202310652804.9A patent/CN117024589A/zh active Pending
- 2020-06-15 US US17/616,799 patent/US20220348665A1/en active Pending
- 2020-06-15 PH PH1/2021/553122A patent/PH12021553122A1/en unknown
- 2020-06-15 BR BR112021025086A patent/BR112021025086A2/pt unknown
- 2020-06-15 WO PCT/KR2020/007704 patent/WO2020251316A1/fr not_active Ceased
- 2020-06-15 CA CA3143242A patent/CA3143242A1/fr active Pending
- 2020-06-15 PE PE2021002067A patent/PE20220516A1/es unknown
- 2020-06-15 EP EP20822425.3A patent/EP3985022A4/fr active Pending
- 2020-06-15 KR KR1020227010688A patent/KR102691493B1/ko active Active
- 2020-06-15 IL IL302490A patent/IL302490A/en unknown
- 2020-06-15 JP JP2021573848A patent/JP7348676B2/ja active Active
- 2020-06-15 MX MX2021015081A patent/MX2021015081A/es unknown
- 2020-06-15 CN CN202080043719.7A patent/CN113966346A/zh active Pending
- 2020-06-15 KR KR1020217018648A patent/KR102444797B1/ko active Active
- 2020-06-15 AU AU2020291487A patent/AU2020291487B2/en active Active
- 2020-06-15 EA EA202193058A patent/EA202193058A1/ru unknown
- 2020-06-15 PE PE2022002215A patent/PE20231029A1/es unknown
2021
- 2021-12-05 IL IL288692A patent/IL288692A/en unknown
- 2021-12-07 MX MX2023006669A patent/MX2023006669A/es unknown
- 2021-12-13 CL CL2021003335A patent/CL2021003335A1/es unknown
- 2021-12-22 CO CONC2021/0017688A patent/CO2021017688A2/es unknown
2022
- 2022-12-08 US US18/063,550 patent/US20230357412A1/en not_active Abandoned
2023
- 2023-04-13 JP JP2023065309A patent/JP7710000B2/ja active Active
- 2023-04-18 ZA ZA2023/04485A patent/ZA202304485B/en unknown
- 2023-04-28 AU AU2023202595A patent/AU2023202595B2/en active Active
- 2023-09-01 JP JP2023141925A patent/JP2023179442A/ja active Pending
2024
- 2024-09-10 US US18/830,263 patent/US20250115670A1/en active Pending
2025
- 2025-09-01 JP JP2025144433A patent/JP2026004290A/ja active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015131258A1 (fr) *	2014-03-06	2015-09-11	National Research Council Of Canada	Anticorps spécifiques du récepteur du facteur de croissance 1 analogues à l'insuline et leurs utilisations
WO2019023809A1 (fr) *	2017-08-02	2019-02-07	Stressmarq Biosciences Inc.	Anticorps se liant à l'alpha-synucléine active
WO2019098763A2 (fr) *	2017-11-17	2019-05-23	에이비엘바이오 주식회사	ANTICORPS ANTI-α-SYNUCLÉINE ET LEURS UTILISATIONS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020251316A1 *

Also Published As

Publication number	Publication date
IL288692A (en)	2022-02-01
KR102691493B1 (ko)	2024-08-05
MX2023006669A (es)	2023-06-21
MX2021015081A (es)	2022-01-18
JP2023113599A (ja)	2023-08-16
KR20210087093A (ko)	2021-07-09
CN113966346A (zh)	2022-01-21
NZ783556A (en)	2025-08-29
US20230357412A1 (en)	2023-11-09
WO2020251316A1 (fr)	2020-12-17
KR102444797B1 (ko)	2022-09-20
US20220348665A1 (en)	2022-11-03
AU2023202595A1 (en)	2023-06-29
CL2021003335A1 (es)	2022-07-15
EP4268842A2 (fr)	2023-11-01
BR112021025086A2 (pt)	2022-01-25
EA202193058A1 (ru)	2022-03-05
PE20220516A1 (es)	2022-04-07
CO2021017688A2 (es)	2022-01-17
JP2026004290A (ja)	2026-01-14
JP7348676B2 (ja)	2023-09-21
CN117024589A (zh)	2023-11-10
IL302490A (en)	2023-06-01
KR20220044397A (ko)	2022-04-07
CA3143242A1 (fr)	2020-12-17
EP3985022A1 (fr)	2022-04-20
JP7710000B2 (ja)	2025-07-17
AU2020291487B2 (en)	2024-11-07
JP2022537279A (ja)	2022-08-25
AU2020291487A1 (en)	2022-01-20
PH12021553122A1 (en)	2022-11-21
PE20231029A1 (es)	2023-07-10
US20250115670A1 (en)	2025-04-10
EP4268842A3 (fr)	2024-05-22
ZA202304485B (en)	2024-08-28
JP2023179442A (ja)	2023-12-19
AU2023202595B2 (en)	2026-03-19

Legal Events

Date	Code	Title	Description
2020-12-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2022-03-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-03-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-04-20	17P	Request for examination filed	Effective date: 20220103
2022-04-20	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-09-21	DAV	Request for validation of the european patent (deleted)
2022-09-21	DAX	Request for extension of the european patent (deleted)
2022-12-23	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40073718 Country of ref document: HK
2023-08-02	A4	Supplementary search report drawn up and despatched	Effective date: 20230705
2023-08-02	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101ALI20230629BHEP Ipc: A61P 25/28 20060101ALI20230629BHEP Ipc: C07K 16/28 20060101ALI20230629BHEP Ipc: C07K 16/18 20060101AFI20230629BHEP

Publication	Publication Date	Title
EP4008730A4 (fr)	2023-09-06	Anticorps anti-ctla4-anti-pd-1 bispécifique et ses utilisations
EP3889174A4 (fr)	2024-07-24	Anticorps bispécifique de type homodimère dirigé contre her2 et cd3, et son utilisation
DK3993876T3 (en)	2024-12-02	Anti-cd154 antibodies and uses thereof
EP3725806A4 (fr)	2022-03-30	Anticorps bispécifique contre a-syn/igf1r et utilisation associée
EP3901172A4 (fr)	2023-01-11	Anticorps humanisé anti-pd-1 et utilisation correspondante
EP3997127A4 (fr)	2023-08-23	Anticorps ciblant la dll3 et leurs utilisations
EP3985022A4 (fr)	2023-08-02	ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE
EP3847196A4 (fr)	2023-01-04	Protéines de liaison à un antigène bispécifiques et leurs utilisations
EP4039704A4 (fr)	2023-09-20	Anticorps anti-pd-1 et son utilisation
EP3778635A4 (fr)	2022-01-26	Anticorps anti-pd-l1 et son utilisation
AU2021383901A9 (en)	2024-10-03	Bispecific antibody and use thereof
EP4001308A4 (fr)	2023-08-23	Anticorps anti-tigit et leur application
EP4455165A4 (fr)	2025-06-04	Anticorps bispécifique et son utilisation
EP4382541A4 (fr)	2025-04-02	Anticorps bispécifique et son utilisation
EP4041403A4 (fr)	2024-02-28	Anticorps anti-kir3dl3 et leurs utilisations
GB201815045D0 (en)	2018-10-31	Bispecific antibody targeting IL-1R1 and NLPR3
EP3914623A4 (fr)	2022-11-23	Di-anticorps anti-pd-l1 et leur utilisation
EP4071171A4 (fr)	2023-06-28	Anticorps anti-tm4sf4 et son utilisation
EP4048700A4 (fr)	2023-12-06	Anticorps bispécifiques anti-bcma/anti-4-1bb et leurs utilisations
EP4025611A4 (fr)	2023-10-18	Anticorps anti-cxcr2 et leurs utilisations
EP3983435A4 (fr)	2023-03-08	Anticorps anti-talen et leurs utilisations
HK40077385A (en)	2023-03-03	Antibodies against ilt2 and use thereof
HK40076774A (en)	2023-02-17	Anti-cd19 antibodies and uses thereof
HK40077274A (en)	2023-03-03	Anti-kir3dl3 antibodies and uses thereof
HK40071706A (en)	2022-11-11	Anti-il-27 antibodies and uses thereof